Plasma Cell Leukemia (PCL)Phase 2CAREMM-011NCT07652905
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
A Phase 2 study testing CM336, Isatuximab and Bortezomib in people with Plasma Cell Leukemia (PCL), run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
Trial summary
The goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma cell leukemia (pPCL). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Plasma Cell Leukemia (PCL)
- What is being tested?
- CM336, Isatuximab and Bortezomib
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteChina
- Study dates
- 15 Sep 2026to 30 Dec 2031
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to understand and voluntarily sign a written informed consent form (ICF).
- Age 18 to 75 years.
- Newly diagnosed primary plasma cell leukemia (pPCL) according to International Myeloma Working Group (IMWG) criteria, defined as either:
- ≥5% circulating plasma cells on peripheral blood smear; or
- Absolute circulating plasma cell count >2 × 10⁹/L.
- Patients who have received no more than one prior cycle of anti-myeloma therapy before enrollment are eligible.
Show all 27Show fewer
- Measurable disease, defined by at least one of the following:
- Serum M-protein ≥10 g/L as measured by serum protein electrophoresis (SPEP); for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead;
- Urine M-protein ≥200 mg/24 hours;
- If neither serum nor urine M-protein meets the above criteria, involved serum free light chain (FLC) ≥100 mg/L with an abnormal serum FLC ratio (normal range: 0.26-1.65).
- Adequate hepatic function, defined as:
- Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.
- Adequate renal function, defined as creatinine clearance ≥30 mL/min, calculated using the Cockcroft-Gault formula.
- Adequate hematologic function within 7 days prior to enrollment, defined as:
- White blood cell (WBC) count ≥1.5 × 10⁹/L;
- Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L;
- Hemoglobin ≥70 g/L;
- Platelet count ≥50 × 10⁹/L;
- Alternatively, eligibility may be determined by the investigator based on clinical judgment.
- Participants receiving hematopoietic growth factor support, including erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or thrombopoietic agents, must have a washout period of at least 2 weeks between the last administration of growth factor support and screening assessments.
- Participants receiving blood product transfusions must meet the following requirements:
- At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;
- At least 1 week between the last platelet transfusion and platelet count assessment at screening.
- Able and willing to receive protocol-recommended prophylactic anticoagulation therapy.
- Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use effective contraception from the time of signing the informed consent form, throughout study treatment, and for at least 3 months after the last dose of study treatment.
- Male participants, including those who have undergone vasectomy, must agree to use condoms during sexual intercourse with women of childbearing potential and must not plan to father a child from the time of signing informed consent through 3 months after the last dose of study treatment.
Who cannot join
- Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or secondary plasma cell leukemia.
- Central nervous system (CNS) involvement or clinical evidence of leptomeningeal involvement.
- Known intolerance, hypersensitivity, allergy, or contraindication to CM336, isatuximab, bortezomib or lenalidomide.
- Severe and/or uncontrolled cardiovascular disease, including:
- Unstable angina; Symptomatic congestive heart failure; Myocardial infarction within 6 months prior to enrollment; Severe and uncontrolled cardiac arrhythmias; Any other cardiovascular or cerebrovascular condition deemed by the investigator to make participation inappropriate.
- Active infection, including:
Show all 15Show fewer
- Human immunodeficiency virus (HIV) infection; Active hepatitis B infection (HBV DNA positive); Active hepatitis C infection (HCV RNA positive); Active or latent syphilis infection (positive Treponema pallidum antibody test); Active pulmonary tuberculosis, as evidenced by chest imaging or other relevant assessments within 3 months prior to screening or during the screening period; Any other infection considered by the investigator to make participation inappropriate.
- Concurrent active malignancy or any serious concomitant disease that, in the investigator's judgment, could compromise participant safety or interfere with study participation.
- Pregnant or breastfeeding women.
- Estimated life expectancy of less than 6 months.
- Active gastrointestinal disorders that may impair the participant's ability to swallow oral medication or may interfere with the absorption of study treatment.
- Major surgery within 2 weeks prior to enrollment (e.g., surgery requiring general anesthesia), incomplete recovery from prior surgery, or planned major surgery during study participation. Kyphoplasty and vertebroplasty are not considered major surgery. Participants undergoing procedures under local anesthesia may be eligible.
- Receipt of a live attenuated vaccine within 4 weeks before the first dose of study treatment.
- Any active severe psychiatric disorder, medical condition, symptom, or other circumstance that, in the investigator's judgment, may interfere with treatment, protocol compliance, or the ability to provide informed consent.
- Inability or unwillingness to provide written informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000
Gang An, PhD & MD, +0086 13502181109, angang@ihcams.ac.cn
About this study
Official title: A Prospective, Single-Arm, Single-Center, Phase II Study Evaluating the Safety and Efficacy of CM336 in Combination With Isatuximab, Lenalidomide, and Bortezomib in Newly Diagnosed Primary Plasma Cell Leukemia
The goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination.
The main questions it aims to answer are:
Read more
How many participants achieve minimal residual disease (MRD) negativity after 9 treatment cycles? What side effects occur during treatment with CM336 combined with isatuximab, lenalidomide, and bortezomib? How many participants respond to treatment, and how long do those responses last? How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study.
Participants will:
Receive CM336 by subcutaneous injection together with isatuximab, lenalidomide, and bortezomib in 28-day treatment cycles.
Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety.
Have stem cells collected after the first 3 treatment cycles if appropriate. Continue treatment for up to 18 cycles, followed by maintenance treatment with isatuximab and lenalidomide until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision.
Be monitored throughout the study for side effects.
- Conditions
- Plasma Cell Leukemia (PCL)
- Being tested
- CM336, Isatuximab, Bortezomib, Lenalidomide
- Keywords
- BCMA/CD3 bispecific antibody, CM336, Primary plasma cell leukemia
- Medical subject headings
- Leukemia, Plasma Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CM336Drug
CM336 is administered subcutaneously (SC) using a step-up dosing regimen, followed by a target dose of 160 mg. During Cycle 1, CM336 is administered weekly; from Cycle 2 through Cycle 18, it is administered every 4 weeks.
IsatuximabDrug
Isatuximab is administered intravenously (IV) at 10 mg/kg. It is given weekly during Cycle 1, every 2 weeks during Cycles 2-12, and every 4 weeks during Cycles 13-18.
BortezomibDrug
Bortezomib is administered subcutaneously (SC) at 1.3 mg/m² once weekly during Cycles 1-18.
LenalidomideDrug
Lenalidomide is administered orally at 25 mg once daily on Days 1-21 of each 28-day cycle.
| Study group | Role | What they receive |
|---|---|---|
| CM336 plus Isa-VR | Experimental | Enrolled patients will receive 18 cycles of therapy with CM336 in combination with isatuximab, bortezomib and lenalidomide Receives: Drug: CM336; Drug: Isatuximab; Drug: Bortezomib; Drug: Lenalidomide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Minimal residual disease (MRD) negative rate
Measured: After 9 cycles (each cycle is 28 days)
Secondary outcomes (5)
Incidence and severity of adverse events (AEs)
Measured: From the first dose of CM336 through 30 days after the last dose of CM336, up to approximately 18 months.
Duration of MRD negativity
Measured: From the date of first documented MRD negativity until disease progression, death, or end of follow-up, whichever occurs first, assessed up to approximately 36 months.
Hematological Overall Response Rate (ORR)
Measured: Up to 18 treatment cycles, each cycle is 28 days
Progression-free survival (PFS)
Measured: From the first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, up to approximately 36 months.
Overall survival (OS)
Measured: From the first dose of study treatment until death from any cause, up to approximately 36 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start15 Sep 2026 (estimated)
- Primary completion30 Jun 2029 (estimated)
- Study completion30 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plasma Cell Leukemia (PCL)Studies of the same condition, open and under way.
- More trials run by Institute of Hematology & Blood Diseases Hospital, ChinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07652905
- Sponsor's protocol ID
- IIT2026071
- Acronym
- CAREMM-011
- Status last verified
- Aug 2026
- First submitted
- 8 Jun 2026
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-Arm, Single-Center, Phase II Study Evaluating the Safety and Efficacy of CM336 in Combination With Isatuximab, Lenalidomide, and Bortezomib in Newly Diagnosed Primary Plasma Cell Leukemia
- ClinicalTrials.gov ID
- NCT07652905
- Acronym / sponsor ID
- CAREMM-011 / IIT2026071
- Conditions
- Plasma Cell Leukemia (PCL)
- Keywords
- BCMA/CD3 bispecific antibody, CM336, Primary plasma cell leukemia
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaUniversity, hospital or other
- Study start
- 15 Sep 2026 (estimated)
- Primary completion
- 30 Jun 2029 (estimated)
- Study completion
- 30 Dec 2031 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination.
The main questions it aims to answer are:
How many participants achieve minimal residual disease (MRD) negativity after 9 treatment cycles? What side effects occur during treatment with CM336 combined with isatuximab, lenalidomide, and bortezomib? How many participants respond to treatment, and how long do those responses last? How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study.
Participants will:
Receive CM336 by subcutaneous injection together with isatuximab, lenalidomide, and bortezomib in 28-day treatment cycles.
Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety.
Have stem cells collected after the first 3 treatment cycles if appropriate. Continue treatment for up to 18 cycles, followed by maintenance treatment with isatuximab and lenalidomide until disease progression, unacceptable toxicity, withdrawal of consent, or investigator decision.
Be monitored throughout the study for side effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CM336 plus Isa-VR | Experimental | Drug: CM336, Drug: Isatuximab, Drug: Bortezomib, Drug: LenalidomideEnrolled patients will receive 18 cycles of therapy with CM336 in combination with isatuximab, bortezomib and lenalidomide |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (27 listed)
- Able to understand and voluntarily sign a written informed consent form (ICF).
- Age 18 to 75 years.
- Newly diagnosed primary plasma cell leukemia (pPCL) according to International Myeloma Working Group (IMWG) criteria, defined as either:
- Patients who have received no more than one prior cycle of anti-myeloma therapy before enrollment are eligible.
- Measurable disease, defined by at least one of the following:
Key exclusion criteria (15 listed)
- Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or secondary plasma cell leukemia.
- Central nervous system (CNS) involvement or clinical evidence of leptomeningeal involvement.
- Known intolerance, hypersensitivity, allergy, or contraindication to CM336, isatuximab, bortezomib or lenalidomide.
- Severe and/or uncontrolled cardiovascular disease, including:
- Unstable angina; Symptomatic congestive heart failure; Myocardial infarction within 6 months prior to enrollment; Severe and uncontrolled cardiac arrhythmias; Any other cardiovascular or cerebrovascular condition deemed by the investigator to make participation inappropriate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CM336CM336 is administered subcutaneously (SC) using a step-up dosing regimen, followed by a target dose of 160 mg. During Cycle 1, CM336 is administered weekly; from Cycle 2 through Cycle 18, it is administered every 4 weeks. | Drug | CM336 plus Isa-VR |
| IsatuximabIsatuximab is administered intravenously (IV) at 10 mg/kg. It is given weekly during Cycle 1, every 2 weeks during Cycles 2-12, and every 4 weeks during Cycles 13-18. | Drug | CM336 plus Isa-VR |
| BortezomibBortezomib is administered subcutaneously (SC) at 1.3 mg/m² once weekly during Cycles 1-18. | Drug | CM336 plus Isa-VR |
| LenalidomideLenalidomide is administered orally at 25 mg once daily on Days 1-21 of each 28-day cycle. | Drug | CM336 plus Isa-VR |
Primary outcome
Minimal residual disease (MRD) negative rate
Time frame: After 9 cycles (each cycle is 28 days)
5 secondary outcomes
Incidence and severity of adverse events (AEs)
Time frame: From the first dose of CM336 through 30 days after the last dose of CM336, up to approximately 18 months.
Duration of MRD negativity
Time frame: From the date of first documented MRD negativity until disease progression, death, or end of follow-up, whichever occurs first, assessed up to approximately 36 months.
Hematological Overall Response Rate (ORR)
Time frame: Up to 18 treatment cycles, each cycle is 28 days
Progression-free survival (PFS)
Time frame: From the first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, up to approximately 36 months.
Overall survival (OS)
Time frame: From the first dose of study treatment until death from any cause, up to approximately 36 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Plasma Cell Leukemia (PCL)
RecruitingPhase 3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
RecruitingPhase 2
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)
Not yet recruitingEarly Phase 1
IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL)
RecruitingEarly Phase 1
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
RecruitingPhase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing CM336, Isatuximab and Bortezomib in people with Plasma Cell Leukemia (PCL), run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 27 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gang An, PhD & MD (+86 13502181109, angang@ihcams.ac.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Minimal residual disease (MRD) negative rate (time frame: After 9 cycles (each cycle is 28 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.